Eyenovia (NASDAQ:EYEN) Shares Set to Reverse Split on Monday, February 3rd

Eyenovia, Inc. (NASDAQ:EYEN) shares are scheduled to reverse split on the morning of Monday, February 3rd. The 1-80 reverse split was announced on Tuesday, January 28th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 31st.

Eyenovia Stock Down 34.7 %

Eyenovia stock opened at $0.04 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. The business’s 50-day simple moving average is $0.09 and its two-hundred day simple moving average is $0.46. The company has a market cap of $4.15 million, a PE ratio of -0.05 and a beta of 1.31. Eyenovia has a fifty-two week low of $0.04 and a fifty-two week high of $2.57.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the business earned ($0.18) EPS. Equities analysts anticipate that Eyenovia will post -0.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EYEN. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. HC Wainwright cut Eyenovia from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $12.00 to $2.00 in a report on Monday, November 18th. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th. Finally, William Blair reissued a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th.

Hedge Funds Weigh In On Eyenovia

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after purchasing an additional 149,471 shares during the last quarter. Financial Management Network Inc. acquired a new stake in shares of Eyenovia in the third quarter valued at approximately $39,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eyenovia in the second quarter valued at approximately $26,000. Finally, Nations Financial Group Inc. IA ADV increased its holdings in shares of Eyenovia by 78.6% in the third quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after purchasing an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.